TESARO (TSRO) Posts Q4 Loss of $2.60/Share

TESARO (NASDAQ: TSRO) reported Q4 EPS of ($2.60), $0.65 worse than the analyst estimate of ($1.95). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $5.76 million.

• Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underway
• Expanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H 2017
• Positive opinion rendered for VARUBY® by the European Medicine Agency’s CHMP; European launch planned for 2Q 2017
• International headquarters and European operations established to cover 17 target countries
• Registration program for niraparib in lung cancer to be finalized in 1H 2017
• TSR-042 (anti-PD-1 antibody) registration program to initiate in 2Q 2017
• Cash and cash equivalents totaled approximately $786 million as of December 31, 2016

For earnings history and earnings-related data on TESARO (TSRO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Vivos Therapeutics posts 35% revenue gain but widens net loss